TARGIT™ technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract

Authors: Watts, Peter; Smith, Alan

Source: Expert Opinion on Drug Delivery, Volume 2, Number 1, 1 January 2005 , pp. 159-167(9)

Publisher: Informa Healthcare

Buy & download fulltext article:


Price: $99.00 plus tax (Refund Policy)


TARGIT™ technology (West Pharmaceutical Services) is designed for site-specific delivery of drugs in the gastrointestinal (GI) tract and, in particular, targeted release into the colonic region. A key area of application is the delivery of therapeutic agents for local treatment of lower GI diseases. The technology is based on the application of pH-sensitive coatings onto injection-moulded starch capsules. An extensive body of clinical data has been generated showing reliable invivo performance of the capsules. In -scintigraphy studies around 90% of TARGIT capsules (n = 84) delivered their contents to the target site of the terminal ileum and colon. TARGIT-based products are in active clinical development for the treatment of conditions including inflammatory bowel diseases.

Keywords: colon; pH-sensitive coating; site-specific; starch capsule

Document Type: Miscellaneous

DOI: http://dx.doi.org/10.1517/17425247.2.1.159

Publication date: January 1, 2005

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page